The leaves of Aster glehni Fr. Schm. (Asteraceae) have been used to treat insomnia in Korea. Insomnia is a common adverse effect of therapeutic agents for Alzheimer's disease (AD), and the control of sleep disturbance may prevent dementia. We hypothesized that the leaves of A. glehni can attenuate cognitive dysfunctions observed in AD. We observed the ameliorating effects of the ethanolic extract of leaves of A. glehni (AG-D) on memory dysfunction through the Morris water maze test, the passive avoidance test, and the Y-maze test. We performed acetylcholinesterase (AChE) activity assay and Western blotting to determine the mechanism of action of AG-D. AG-D significantly attenuated memory dysfunction observed in the above behavior studies and inhibited the activity of AChE. AG-D also increased the levels of phosphorylation extracellular signal-regulated kinase (ERK), cAMP response element-binding protein (CREB), phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), and glycogen synthase kinase 3β (GSK-3β) and the expression levels of brain-derived neurotrophic factor (BDNF) in the hippocampi. These results suggest that AG-D ameliorates memory impairments by AChE inhibition and activation of ERK-CREB-BDNF and PI3K-Akt-GSK-3β signaling pathways. Taken together, this study suggests that AG-D could be used as a potential treatment for cognitive dysfunction.
Get full access to this article
View all access options for this article.
References
1.
HiremathadA, KeriRS, EstevesAR, CardosoSM, ChavesS, SantosMA: Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease. Eur J Med Chem, 2018; 148:255–267.
2.
KarthivashanG, GanesanP, ParkSY, KimJS, ChoiDK: Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease. Drug Deliv, 2018; 25:307–320.
3.
SinghM, KaurM, KukrejaH, ChughR, SilakariO, SinghD: Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection. Eur J Med Chem, 2013; 70:165–188.
4.
LimYY, MaruffP, SchindlerR, et al.: Disruption of cholinergic neurotransmission exacerbates Abeta-related cognitive impairment in preclinical Alzheimer's disease. Neurobiol Aging, 2015; 36:2709–2715.
5.
PepeuG, Grazia GiovanniniM: The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Res, 2017; 1670:173–184.
6.
Van der ZeeEA, PlattB, RiedelG: Acetylcholine: Future research and perspectives. Behav Brain Res, 2011; 221:583–586.
7.
NwiduLL, ElmorsyE, ThorntonJ, et al.: Anti-acetylcholinesterase activity and antioxidant properties of extracts and fractions of Carpolobia lutea. Pharm Biol, 2017; 55:1875–1883.
8.
MusialA, BajdaM, MalawskaB: Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem, 2007; 14:2654–2679.
9.
MurrayAP, FaraoniMB, CastroMJ, AlzaNP, CavallaroV: Natural AChE inhibitors from plants and their contribution to Alzheimer's disease therapy. Curr Neuropharmacol, 2013; 11:388–413.
10.
BaeJS, KimTH. 2009. Acetylcholinesterase inhibitory and antioxidant properties of Aster yomena extract. Kor J Herbology, 24:121–126.
11.
LeeYJ, JangYN, HanYM, et al.: Caffeoylquinic acid-rich extract of Aster glehni F. Schmidt ameliorates nonalcoholic fatty liver through the regulation of PPARdelta and adiponectin in ApoE KO mice. PPAR Res, 2017; 2017:3912567.
12.
LeeHM, YangG, AhnTG, et al.: Antiadipogenic effects of Aster glehni extract: In vivo and in vitro effects. Evid Based Complement Alternat Med, 2013; 2013:859624.
13.
NugrohoA, KimMH, ChoiJ, et al.: Phytochemical studies of the phenolic substances in Aster glehni extract and its sedative and anticonvulsant activity. Arch Pharm Res, 2012; 35:423–430.
14.
PetitD, GagnonJF, FantiniML, Ferini-StrambiL, MontplaisirJ: Sleep and quantitative EEG in neurodegenerative disorders. J Psychosom Res, 2004; 56:487–496.
15.
PrinzPN, PeskindER, VitalianoPP, et al.: Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. J Am Geriatr Soc, 1982; 30:86–93.
16.
DringenbergHC: Alzheimer's disease: More than a “cholinergic disorder”—Evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res, 2000; 115:235–249.
17.
Pat-HorenczykR, KlauberMR, ShochatT, Ancoli-IsraelS: Hourly profiles of sleep and wakefulness in severely versus mild-moderately demented nursing home patients. Aging (Milano), 1998; 10:308–315.
18.
SekiguchiH, IritaniS, FujitaK: Bright light therapy for sleep disturbance in dementia is most effective for mild to moderate Alzheimer's type dementia: A case series. Psychogeriatrics, 2017; 17:275–281.
19.
SpiraAP, GottesmanRF: Sleep disturbance: An emerging opportunity for Alzheimer's disease prevention?. Int Psychogeriatr, 2017; 29:529–531.
20.
SeoS, LeeKG, ShinJS, et al.: 6′-O-Caffeoyldihydrosyringin isolated from Aster glehni suppresses lipopolysaccharide-induced iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 expression via NF-kappaB and AP-1 inactivation in RAW 264.7 macrophages. Bioorg Med Chem Lett, 2016; 26:4592–4598.
21.
JungWY, KimH, ParkHJ, et al.: The ethanolic extract of the Eclipta prostrata L. ameliorates the cognitive impairment in mice induced by scopolamine. J Ethnopharmacol, 2016; 190:165–173.
22.
ParkSJ, KimDH, LeeIK, et al.: The ameliorating effect of the extract of the flower of Prunella vulgaris var. lilacina on drug-induced memory impairments in mice. Food Chem Toxicol, 2010; 48:1671–1676.
23.
KimH, LeeHE, JungIH, et al.: The memory ameliorating effects of DHP1402, an herbal mixture, on cholinergic blockade-induced cognitive dysfunction in mice. J Ethnopharmacol, 2018; 211:38–46.
24.
SarterM, BodewitzG, StephensDN: Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology, 1988; 94:491–495.
25.
KimE, KoHJ, JeonSJ, et al.: The memory-enhancing effect of erucic acid on scopolamine-induced cognitive impairment in mice. Pharmacol Biochem Behav, 2016; 142:85–90.
26.
EllmanGL, CourtneyKD, AndresVJr., Feather-StoneRM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 1961; 7:88–95.
27.
JeonSJ, KimB, RyuB, et al.: Biflorin ameliorates memory impairments induced by cholinergic blockade in mice. Biomol Ther (Seoul), 2017; 25:249–258.
28.
LiaoY, BaeHJ, ZhangJ, et al.: The ameliorating effects of bee pollen on scopolamine-induced cognitive impairment in mice. Biol Pharm Bull, 2019; 42:379–388.
29.
KimDH, LeeY, LeeHE, et al.: Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice. Brain Res Bull, 2014; 108:67–73.
30.
KwonSH, LeeHK, KimJA, et al.: Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Eur J Pharmacol, 2010; 649:210–217.
31.
GiacobiniE: Cholinesterases: New roles in brain function and in Alzheimer's disease. Neurochem Res, 2003; 28:515–522.
32.
Garcia-AyllonMS, Riba-LlenaI, Serra-BasanteC, AlomJ, BoopathyR, Saez-ValeroJ: Altered levels of acetylcholinesterase in Alzheimer plasma. PloS One, 2010; 5:e8701.
33.
KelleherRJ3rd, GovindarajanA, JungHY, KangH, TonegawaS: Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell, 2004; 116:467–479.
LiY, LiX, GuoC, et al.: Long-term neurocognitive dysfunction in offspring via NGF/ERK/CREB signaling pathway caused by ketamine exposure during the second trimester of pregnancy in rats. Oncotarget, 2017; 8:30956–30970.
36.
KangBH, JoI, EunSY, JoSA: Cyclic AMP-dependent protein kinase A and CREB are involved in neuregulin-induced synapse-specific expression of acetylcholine receptor gene. Biochem Biophys Res Commun, 2003; 304:758–765.
37.
PortoRR, DutraFD, CrestaniAP, et al.: HSP70 facilitates memory consolidation of fear conditioning through MAPK pathway in the hippocampus. Neuroscience, 2018; 375:108–118.
38.
BenitoE, BarcoA: CREB's control of intrinsic and synaptic plasticity: Implications for CREB-dependent memory models. Trends Neurosci, 2010; 33:230–240.
39.
RestivoL, TafiE, Ammassari-TeuleM, MarieH: Viral-mediated expression of a constitutively active form of CREB in hippocampal neurons increases memory. Hippocampus, 2009; 19:228–234.
40.
YiuAP, RashidAJ, JosselynSA: Increasing CREB function in the CA1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology, 2011; 36:2169–2186.
41.
AllenSJ, WatsonJJ, ShoemarkDK, BaruaNU, PatelNK: GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther, 2013; 138:155–175.
KimDH, KimJM, ParkSJ, et al.: GABA(A) receptor blockade enhances memory consolidation by increasing hippocampal BDNF levels. Neuropsychopharmacology, 2012; 37:422–433.
44.
LeyheT, StranskyE, EschweilerGW, BuchkremerG, LaskeC: Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci, 2008; 258:124–128.
45.
LapchakPA, AraujoDM, HeftiF: Cholinergic regulation of hippocampal brain-derived neurotrophic factor mRNA expression: Evidence from lesion and chronic cholinergic drug treatment studies. Neuroscience, 1993; 52:575–585.
46.
KamelAS, AbdelkaderNF, Abd El-RahmanSS, EmaraM, ZakiHF, KhattabMM: Stimulation of ACE2/ANG(1-7)/Mas axis by diminazene ameliorates Alzheimer's disease in the d-galactose-ovariectomized rat model: Role of PI3K/Akt pathway. Mol Neurobiol, 2018; 55:8188–8202.
47.
KellyA, LynchMA: Long-term potentiation in dentate gyrus of the rat is inhibited by the phosphoinositide 3-kinase inhibitor, wortmannin. Neuropharmacology, 2000; 39:643–651.
48.
SanchetiH, AkopianG, YinF, BrintonRD, WalshJP, CadenasE: Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. PloS One, 2013; 8:e69830.
49.
PeltierJ, O'NeillA, SchafferDV: PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev Neurobiol, 2007; 67:1348–1361.
50.
WangY, WuC, HanB, et al.: Dexmedetomidine attenuates repeated propofol exposure-induced hippocampal apoptosis, PI3K/Akt/Gsk-3beta signaling disruption, and juvenile cognitive deficits in neonatal rats. Mol Med Rep, 2016; 14:769–775.
51.
TaoG, XueQ, LuoY, LiG, XiaY, YuB: Isoflurane is more deleterious to developing brain than desflurane: The role of the Akt/GSK3beta signaling pathway. Biomed Res Int, 2016; 2016:7919640.
52.
ShiX, MillerJS, HarperLJ, PooleRL, GouldTJ, UnterwaldEM: Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibition. Psychopharmacology, 2014; 231:3109–3118.
53.
ParkSJ, KimDH, JungJM, et al.: The ameliorating effects of stigmasterol on scopolamine-induced memory impairments in mice. Eur J Pharmacol, 2012; 676:64–70.
54.
JeonSJ, LeeHJ, LeeHE, et al.: Oleanolic acid ameliorates cognitive dysfunction caused by cholinergic blockade via TrkB-dependent BDNF signaling. Neuropharmacology, 2017; 113(Pt A):100–109.
55.
ChoiJH, ChungKS, JinBR, et al.: Anti-inflammatory effects of an ethanol extract of Aster glehni via inhibition of NF-kappaB activation in mice with DSS-induced colitis. Food Funct, 2017; 8:2611–2620.
56.
ChoJY, KimJY, LeeYG, et al.: Four new dicaffeoylquinic acid derivatives from glasswort (Salicornia herbacea L.) and their antioxidative activity. Molecules, 2016; 21.
57.
YoshimotoM, YaharaS, OkunoS, IslamMS, IshiguroK, YamakawaO: Antimutagenicity of mono-, di-, and tricaffeoylquinic acid derivatives isolated from sweetpotato (Ipomoea batatas L.) leaf. Biosci Biotechnol Biochem, 2002; 66:2336–2341.
58.
MiyamaeY, KurisuM, MurakamiK, et al.: Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid beta-protein. Bioorg Med Chem, 2012; 20:5844–5849.
59.
KangJY, ParkSK, GuoTJ, et al.: Reversal of trimethyltin-induced learning and memory deficits by 3,5-dicaffeoylquinic acid. Oxid Med Cell Longev, 2016; 2016:6981595.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
